CJC-1295 no DAC / lpamorelin
A 1:1 blend of CJC-1295 no DAC and Ipamorelin designed for research on growth hormone secretion and pituitary signaling pathways.
About CJC-1295 no DAC / lpamorelin
This blend combines CJC-1295 no DAC, a long-acting GHRH analog, with Ipamorelin, a selective ghrelin receptor (GHSR-1a) agonist. Together, they are frequently used in research models to study coordinated stimulation of growth hormone release through both hypothalamic and pituitary pathways. CJC-1295 is often examined for its extended half-life and sustained GH/IGF-1 signaling, while Ipamorelin is valued for its receptor selectivity and limited impact on cortisol and prolactin. The 5mg/5mg formulation provides a balanced profile for investigating synergistic GH pulse dynamics, metabolic regulation, and endocrine feedback mechanisms.
